MC2R MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1); or a salt thereof, wherein A, Z, X, L1, L2, L3, RA, RB, RC, RD, Y1 and Y2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the melanocortin subtype-2...

Full description

Saved in:
Bibliographic Details
Main Authors SANDERSON, Adam Jan, SANZ, Laia Malet, BROWN, Giles Albert, TEHAN, Benjamin, MUSGAARD, Maria
Format Patent
LanguageEnglish
French
Published 29.08.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosures herein relate to novel compounds of Formula (1); or a salt thereof, wherein A, Z, X, L1, L2, L3, RA, RB, RC, RD, Y1 and Y2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with the melanocortin subtype-2 receptor (MC2R). L'invention concerne de nouveaux composés de formule (1) ; ou un sel de celui-ci, A, Z, X, L1, L2, L3, RA, RB, RC, RD, Y1 et Y2 étant tels que définis dans la description, et leur utilisation dans le traitement, la prévention, l'amélioration, la régulation ou la réduction du risque de troubles associés au récepteur de sous-type 2 de mélanocortine (MC2R).
Bibliography:Application Number: WO2024GB50500